UNSPSC 51143203: Varenicline

This classification denotes a nicotinic agonist with the molecular formula C13H13N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6HS99O8ZO, chemically known as 7,8,9,10-tetrahydro-6,10-methano-6h-pyrazino(2,3-h)(3)benzazepine but generally known as varenicline, which bears US NIH Compound Identifier 170361. European Medicines Agency schedules Varenicline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25195.

World Health Organization schedules varenicline in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule varenicline under HS 29333999 and SITC 51574. As of Q4 2014, VARENICLINE remains the US FDA Preferred Term for this commodity. Varenicline bears US NLM identifiers UMLS ID C1569608 and NCI Concept Code C73609. SMILES: N1CC2CC(C3C2CC2NCCNC2C3)C1.

UNSPSC 51143203 Varenicline is a Commodity code that encompasses pharmaceutical products used in smoking cessation and substance-use interventions. State and local governments procure under this code to support public health initiatives, including community health departments, county health systems, and state human services agencies managing population health programs, addiction treatment, and emergency response capabilities. The recent opportunities posted under this code show procurement of naloxone (an opioid overdose reversal medication) and related drug deactivation systems rather than varenicline itself, indicating that state and local buyers use the code broadly for pharmaceutical interventions addressing substance-use disorders and emergency public health needs. Issuing bodies range from county health departments to state health and human services commissions, with each managing their own procurement cycles and delivery requirements.

Seminole County, Florida posted an IFB (Invitation for Bid) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI) on April 3, 2026, exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in restructuring pharmaceutical procurement channels and negotiated pricing models outside traditional pharmacy benefit manager arrangements. Recent activity concentrates in Florida and Texas, with procurement driven by both emergency response needs (naloxone distribution) and strategic pharmacy benefit program redesign at the state level. Both opportunities require vendors to meet standard compliance benchmarks including E-Verify authorization, drug-free workplace certification, and appropriate insurance coverage.